Diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer originating from mature 15 B-cells. Many known driver mutations are over-represented in one of its two molecular sub- 16 groups, knowledge of which has aided in the development of therapeutics that target these 17 features. The heterogeneity of DLBCL determined through prior genomic analysis suggests 18 an incomplete understanding of its molecular aetiology, with a limited diversity of genetic 19 events having thus far been attributed to the activated B-cell (ABC) subgroup. Through an 20 integrative genomic analysis we uncovered genes and non-coding loci that are commonly mu-21 tated in DLBCL including putative regulatory sequences. We implicate recurrent mutations 22 in the 3 UTR of NFKBIZ as a novel mechanism of oncogene deregulation and found small 23 amplifications associated with over-expression of FC-γ receptor genes. These results inform 24 on mechanisms of NF-κB pathway activation in ABC DLBCL and may reveal a high-risk 25 population of patients that might not benefit from standard therapeutics. 26 29 activity pathways, the latter being particularly active in ABC cases 1 . EZH2 2 , SGK1, GNA13 and 30 MEF2B 2 exemplify genes with mutations restricted to GCB cases, whereas MYD88 3 , CD79B 4 and 31 CARD11 5 have been reported as more commonly mutated in ABC. Some DLBCL cases have few 32 (if any) genetic alterations strongly associated with either subgroup, suggesting the possibility of 33 additional genetic or epigenetic changes that shape the malignancy. Similarly, the over-expression 34 2 of proteins with potential therapeutic and clinical relevance cannot always be explained by known 35 genetic alterations 6 . Gaining a more complete understanding of the genetic features of DLBCL in 36 general and each subgroup in particular should lead to improved methods for this sub-classification 37 and further inform on the molecular and genetic underpinnings of the lymphoma found in indi-38 vidual patients. Such enhancements have the potential to facilitate the development of targeted 39 therapies, such as small molecule inhibitors 7 , new monoclonal antibodies and immunotherapies 40 that target somatic mutations or cell surface proteins 8 .
Introduction 27
It has been established that DLBCL, although genetically heterogeneous, can be robustly divided at 28 the gene expression level into two subgroups based on markers of B-cell differentiation and NF-κB genes in DLBCL 14 . Specifically, in DLBCL and several other lymphoid cancers the AID enzyme Local Mutation Density and Somatic Cis-regulatory Variation 116 We next sought genes with patterns of non-silent mutations, beginning with a meta-analysis of the 117 genomes and all available exome data for recurrently mutated genes. The genes significantly af-118 fected by SSMs had mostly been identified in prior studies and a large exome study published while 119 this manuscript was being completed 10 (Extended Data: Figure 4 , Table 1 ). Among the genes that 120 have limited prior evidence for relevance in DLBCL, many have been implicated in other B-cell 121 lymphomas arising within the germinal centre. For example, DDX3X, ARID1A and HVCN1 which 122 have been reported as recurrently mutated in Burkitt lymphoma (BL) 25 and follicular lymphoma 123 (FL) 26 . 124 Within the 153 genomes, we identified between 1689 and 121,694 SSMs (median: 14,026) . 125 We searched genome-wide for patterns of mutation that may imply regulatory function without 126 directly impacting protein sequence. To accomplish this, we implemented a new strategy to infer 127 regions of arbitrary span with mutation density elevated above the local background. The method 128 considers positions of pooled mutations from a cohort of cancer genomes excluding any variants 129 also revealed examples of non-coding loci with mutation peaks, for example the two adjacent 136 long noncoding RNA (lncRNA) genes NEAT1 and MALAT1 and the miR-142 locus ( Figure 3C ). 137 Mutations at each of these loci have been previously noted in other DLBCL and FL and their 138 pattern is consistent with aSHM 27, 28 . 139 To determine the suitability of our approach to identify mutation clusters relevant to DL-140 BCL, we extended our peak analysis to include all mutations including the coding region (CDS). 141 We found a similar number of peaks (4, 405) , which comprised the bulk of the original non-coding 142 peaks as well as peaks in genes with mutation hot spots such as EZH2, FOXO1 and MYD88 (Fig-143 ure 3B). Aside from intergenic regions (2,244), the top three classes of annotation affected by 144 peaks were 5 flanking regions, 5 UTRs and introns. These are also the regions typically affected 145 by aSHM and, as expected, virtually all of the known targets of this process were represented 146 among these regions 12, 14 . We also noted multiple genes with mutation patterns consistent with 147 aSHM including the AICDA locus itself, PRDM1, DNMT1, and ACTB ( Figure 3E and Extended 148 Data Figure 3 ). If the mutations in these peaks were largely due to a single mutational process that 149 preferentially acts in certain regions, we expected to find differences in the mutational signatures 150 relative to the full set of SNVs. Interestingly, although the signature attributed to AID and POLν 151 activity was represented genome-wide and within the peaks, another signature that does not clearly 152 correspond to any of the previously described signatures was unique to the peaks (Extended Data 153 Figure 5 ).
154
To identify peaks with potential relevance in modulating transcription, we assessed the rela-155 8 tionship between gene expression and the presence of mutations in nearby peaks. All genes with 156 one or more proximal peak were tested for significant differences in expression between mutated 157 and un-mutated cases (Extended Data Figure 6 ). Most of the protein-coding loci identified were 158 known (including SERPINA9, CD44, PIM1) or the novel targets of aSHM we had identified (in-159 cluding DNMT1 and AICDA). The correlation between expression and aSHM is typically attributed 160 to an elevated AID activity at highly expressed genes and thus may act as a permanent marker of 161 sustained expression of these genes rather than representing driver mutations. Regardless, the 162 unprecedented breadth of mutations affecting potential regulatory regions including enhancers 163 proximal to these genes suggests the possibility of a regulatory effect and this warrants further 164 investigation. To enrich for genes with patterns unlikely to result from aSHM, we identified loci 165 for which the most common variant annotation in each peak was not among the classes attributable 166 to aSHM. Multiple genes showed distinct distributions of mutations seemingly inconsistent with 167 aSHM. This could imply a different mutational process or the action of selective pressure to retain 168 or alter function. Some of these genes had short 5 UTRs and thus had mutations within their CDS 169 and even 3 UTRs (e.g. MPEG1, HIST1H1C). In longer genes, such as NFKBIZ, 3 UTR mutations 170 cannot be readily attributed to aSHM and appear to indicate strong selective pressure.
171
Recurrently Mutated Loci Associated With Cell-of-origin Subgroup
172
Our genome analysis uncovered a striking pattern of mutations in NFKBIZ, a gene that has been 173 reported to act as an oncogene in DLBCL cases with copy number amplification affecting this 174 locus 29 though other somatic mutations affecting this region appear to be lacking. NFKBIZ was 175 9 significantly more commonly mutated in ABC cases when the 3 UTR mutations are considered and 176 even more strongly enriched in ABC when amplifications affecting this region are also considered 177 (P = 2.15 × 10 −5 , Fisher's Exact Test) . Combining the genome data and results from targeted 178 sequencing in a larger "validation" cohort, we confirmed our observation of a novel pattern of 179 SSMs in the 3 UTR of NFKBIZ as well as some large indels and somatic structural variants (SVs) 180 ( Figure 5 ; Extended Data Figure 7) . To demonstrate the improved resolution power of WGS to 181 detect such mutations, we contrast these results to the large cohort of available exome data, which 182 were uniformly re-analysed with the same methodology and show a much lower yield of these 183 variants. We also compared the prevalence of NFKBIZ 3 UTR mutations in other lymphoid cancers 184 with available WGS data including CLL, FL and BL. FL had the next highest prevalence with 185 these mutations appearing in less than 3% of cases ( Table 2 ). The number of cases also provided 186 sufficient power to determine patterns of mutually exclusive genes within ABC and GCB. One of 187 the few pairs of genes showing mutual exclusivity for mutation in ABC was MYD88 and NFKBIZ, 188 indicating a potentially redundant role of these two mutations in lymphomagenesis (Extended Data 189 Figure 8 ).
190
The 3 UTR of NFKBIZ is highly conserved and the mutated region has been previously 191 identified as a destabilising element that promotes rapid mRNA turnover 30 . We predict these mu-192 tations perturb this process thereby increasing mRNA longevity, which would in turn cause allelic 193 imbalance in mutant cases. We constructed a structural model for the highly conserved region 194 that contained the vast majority of SSMs (Extended Data Figure 9 ), which consists of one large 195 stem-loop with several internal bulges and a smaller stem-loop with pairing in the loops forming 196 10 a pseudoknot. Molecular dynamic simulations of selected mutations show that a subset appears to 197 significantly change the structure relative to wild-type sequence (Extended Data Figure 9 ).
198
Higher mRNA levels were observed among the cases with 3 UTR mutations supporting their 199 role in promoting mRNA abundance. To demonstrate the mutations promote elevated expression 200 in cis, we searched for evidence of allelic imbalance. Of the cases with sufficient RNA-seq depth 201 and at least one heterozygous SNP in NFKBIZ, we identified 25 cases with significant allelic im-202 balance. Roughly half of these cases had mutations that could impact either transcriptional or 203 post-transcriptional regulation, with four containing a structural variation or indel affecting the 204 3 UTR and nine having one or more UTR SNV. This finding suggest that additional genetic or 205 epigenetic alterations may also lead to allelic imbalance in NFKBIZ expression. We identified 206 two DLBCL cell lines (DOHH-2 and SU-DHL-6) with NFKBIZ 3 UTR mutations and two lines 207 (OCI-Ly10 and HBL-1) having NFKBIZ amplification.
208
To confirm this allelic imbalance, we implemented a ddPCR assay that separately quanti-209 fies mutant and wild-type NFKBIZ mRNAs. We tested mRNA extracted from eight DLBCL cell 210 lines and a subset of the patient RNA samples and found that samples with NFKBIZ mutations 211 or amplifications each had significantly higher mRNA levels. We confirmed in the two cell lines 212 with NFKBIZ 3 UTR deletions (DOHH-2 and SU-DHL-6) that the mRNA represented a greater 213 proportion of the mutant allele ( Figure 5 ). When applying this assay to patient RNA samples, we 214 compared the variant allele fractions (VAFs) for the mutation from our ddPCR assay and RNA-seq 215 to the tumour DNA as determined by targeted capture sequencing (Extended Data Figure 10 ). The
216
RNA VAFs were higher than DNA in all NFKBIZ mutant patients, indicating increased expression 217 of the mutant allele. Patient DLC 198 did not have a significant difference between RNA and DNA 218 levels however, this can be attributed to a CNA of the NFKBIZ locus where an extra wild-type al-219 lele was present in this patient. By immunoblot, we confirmed high levels of IκBζ protein in these 220 NFKBIZ mutant cell lines relative to lines lacking these events ( Figure 5 ).
221

Discussion
222
In this study, we have confirmed the recurrence and determined the specificity of non-silent mu-223 tations in a substantial number of genes to the molecular subgroups of de novo DLBCLs. Here, 224 we focus our attention on some of the more common mutational features of DLBCL that were to IgG relative to its other family members 32 . Nonetheless, to date, recurrent somatic alterations 241 promoting deregulated expression of FC-γ receptors have not been addressed. 242 We hypothesised that an imbalanced expression of FC-γ receptor proteins in malignant cells, 243 due in part to the complex focal amplifications we have identified herein, attenuates the normal im-244 mune response to rituximab as has been seen with alternative isoforms and polymorphic variants 245 of this gene. This was strongly supported by the significantly inferior outcome of FCGR2B-high 246 GCB patients treated with R-CHOP ( Figure 2 ) and is consistent with a smaller study that showed 247 a correlation between FCγRIIB protein staining and outcome in FL 33 . In light of this, alternative 248 immunotherapy approaches may be warranted for this high-risk sub-population. Type II mAbs 249 directed at CD20 or other proteins are not internalised by the same process and thus may be ben-250 eficial in these patients. Another potential avenue of exploration is direct targeting of FCγRIIB 251 alone or in combination 34 . Beyond somatic copy number alterations and possibly some influence 252 from germline CNVs, we also identified an elevated level of SSMs in two introns of FCGR2B that 253 may promote intron retention and lead to a truncated isoform. Further exploration of the role of 254 genetic variation in producing FCGR2B over-expression or upsetting the balance of FCGR2B and 255 FCGR2C in DLBCL is warranted. 256 
13
In conjunction with NFKBIZ amplifications, which promote its expression, our data indicate 257 an overall prevalence of 21.5% for mutations that may impact IκBζ protein abundance or function 258 with 35 cases (10%) having at least one 3 UTR mutation. These were more common than coding 259 changes or amplifications of this locus and strongly associate with the ABC subgroup whereas 260 missense mutations were observed in both subgroups. Multiple studies have already attributed 261 a 165 nt region in the UTR that harbours the bulk of the mutations we detected as destabilising 262 elements 30, 35 . The observation of allelic imbalance in many of the patient samples with 3 UTR 263 mutations strongly implicates them in perturbing mRNA turnover but the functional mechanism is 264 not clear. NFKBIZ is one of several genes subject to post-transcriptional regulation by the endori-265 bonucleases Regnase-1 (Reg-1) and Roquin 35 . This process involves mRNA turnover and/or se-266 questration mediated by interactions between these proteins and specific stem-loops in the 3 UTRs 267 of their targets 36 . MYD88, an adaptor protein that is commonly mutated in ABC DLBCLs, has 268 been shown to be important for protecting NFKBIZ mRNA from this process 37 . Moreover, B-269 cell receptor signalling, which is active in most ABC DLBCLs, can also promote stabilisation of 270 NFKBIZ mRNA via the UTR 30 .
271
The role of individual putative structural components in the 3 UTR of NFKBIZ in these indi-272 vidual processes has not been fully elucidated. The region we describe as containing a pseudoknot 273 and comprising the first two stem-loops does not resemble the loop size and nucleotide properties 274 that have been attributed to Roquin 38 , implicating instead the two distal elements in this interaction 275 (SL3 and SL4). Reg-1 is encoded by ZC3H12A, one of the novel recurrently mutated genes iden-276 tified through our meta-analysis (Extended Data Table 1 ). Confirming the mechanism whereby 277 14 3 UTR mutations impact the NF-κB pathway in DLBCL is highly relevant given the growing list 278 of therapeutic strategies designed to inhibit this pathway directly or by perturbing upstream sig-279 nalling events. Notwithstanding that mechanistic details remain unclear, we have demonstrated 280 that higher mRNA and protein levels result from these mutations. To the best of our knowledge, 281 recurrent 3 UTR mutations are the first example of a common somatic UTR alteration that can 282 directly increase the expression of an oncogene. Though previous studies have noted some focal gains affecting this region 9 , we note that SNP arrays have poor coverage of this locus. The signal from copy-number probes on SNP6.0 arrays (black) is compared to binned read coverage (blue) for two cases. Due to a lack of constitutional DNA for the validation cohort, we are unable to determine the proportion of single-copy gains and losses that can be attributed to common germline CNVs. We can, however, identify cases with gains exceeding the complement possible through germline CNVs. (C) The local copy number was determined in the validation cohort using ddPCR and amplifications were carefully discriminated from single-or two-copy gains. The expression of each FCγ receptor gene is shown with the cases separated by copy number state. Within GCB cases, those with amplifications or gains had significantly elevated FCGR2B expression whereas deleted cases showed a trend towards reduced IGLL5  DMD  PLEKHA2  SPRED2  TBC1D4  chr7:61738085  BATF  IGHE  DNMT1  IGHG2  IMMP2L  MAP3K13  PRDM1  ZNF608  CD44  IGLL5   MEF2B  ACTA1  TNFRSF14  BCL2  GNA13  EZH2  IRAK4  BCL2  USP7  IL4R  HVCN1  SOCS1  P2RY8  SOCS1  RB1  REL  DDX3X  PCBP1  GNAI2  CYP2E1  SGK1  CREBBP  S1PR2  STAT6  PRAME  BIRC6  FAS  IRF8  FBXO11  FAS  RPL22  USP32  BCL2  SMARCA4  CDC42EP3  FAM20C  B2M  UBR4  SMYD2  ETV1  KMT2D  SPEN  PHF6  ARID1A  INPP4B  HYDIN  FCGR2B  MIR17HG  CARD11  FOXO1  PCDH7  MYC  EP300  NFKBIA  NFKB1  MYC  ZFP36L1  RHOA  NR3C1  NFKBIE  EZH2  CD58  UBEC3  MEF2B  KLHL6  CDK6  HIST1H1E  RB1  S1PR1  MDM4  EBF1  POU2F1  B2M  B2M  MIR15A  FHIT  NFKBIA  RBL2  GABRB3  KMT2D  MAPK10  POU2AF1  TP53  IRF4  RFX7  POU2F2  KMT2C  ESR1  HIST1H1C  TNFSF14  TMEM30A  CD58  TMEM30A  TP53  ADPRHL1  NFKBIZ  TP63  FOXC1  BTG2  CD58  RBM38  NOTCH1  TNFAIP3  DSG4  TNFAIP3  ZC3H12A  PRIM2  LINC00470  TP53  TOX  MYD88  EBF1  CARD11  CDKN2A  LOC283177  TARP  NFKBIZ  BCL10  GABRB3  CCND3  ATP6V1B2  PIM1  MS4A1  HLA−DOB  BCL6  GHDC  TMSB4X  IRF4  TCF4  NFKBIZ  PIM1  ITPKB  MGRN1  CD79B  NFKBIZ  TBL1XR1  MPEG1  NFKBIZ  MYD88 SPIB CD79B Non-silent mutations, recurrent CNAs and SVs that may be associated with either ABC or GCB COO are shown based on our validation cohort. An asterisk indicates significance at P<0.05.
For genes with mutation hot spots or affected by CNVs or SVs, we considered these mutations separately from other missense variants. (B) Some genome-wide non-coding mutation peaks also showed cell-of-origin differences. Many of these are within genes that encode the immunoglobulin heavy and light chains. Unsurprisingly, the remaining genes overlap considerably with COOassociated genes that are also affected by coding mutations, mainly those affected by aSHM. The differential presence of aSHM activity, likely owing to expression differences, may explain why some of these genes are uniquely mutated in their respective subgroup. The BCL2 locus had multiple peaks that were commonly mutated among GCB cases including multiple intronic regions that appear, based on H3K27Ac patterns, to coincide with an enhancer. These mutations were not restricted to cases with BCL2 translocations. The AICDA locus, a novel aSHM target, is mutated mainly in ABC cases. The BCL6 and PAX5 super-enhancer was preferentially mutated in GCB cases. A peak in GRHPR near PAX5 was more commonly mutated in ABC cases ( Figure 3D ).
The DNMT1 locus is near S1PR2 and both of these peaks were enriched for mutations in GCB, indicating the potential for co-regulation of these genes using a common set of regulatory regions.
(C) Genes with mutations significantly associated with one subgroup are shown above a heat map of the expression of several genes with strong COO-associated expression to highlight the mutual exclusivity between some gene pairs. In ABC, NFKBIZ and MYD88 mutations were mutually exclusive relative to other mutations involved in NF-κB signalling. In GCB, EZH2 and MEF2B hot spot mutations were common in BCL2-translocated cases and in those lacking mutations in assay was applied to eight DLBCL cell lines to determine NFKBIZ mRNA expression levels.
Dark colours indicate total transcript counts and light colours indicate wild-type 3 UTR transcript counts. Cell line NFKBIZ mutations include amplifications (blue), 3 UTR deletions (green) or none (grey). One line (Pfeiffer) lacking any detectable NFKBIZ mutation had elevated NFKBIZ mRNA levels relative to un-mutated lines. We suspect this is due to a STAT3 mutation, as previous studies suggest that STAT3 plays a role in NFKBIZ activation 40, 41 . Cell lines were also assessed by Western blot for IκBζ expression. Only mutant cell lines (green and blue) showed increased 
